Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hutchison Medipharma Limited
This phase II trial will evaluate the combination of fruquintinib and gefitinib in advanced NSCLC. The endpoint will be to evaluate the efficacy and safety of the combination.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent Form.
Age between 18 to 75 years old.
Histologically or cytological documented stage IIIB/IV non-squamous non-small cell lung cancer patients who have never received systematic treatment for the late-stage disease.
ECOG 0-1
Patients must have measurable lesions
You may not be if
Prior systematic treatment for the advanced NSCLC
Absolute neutrophil count (ANC) \< 1.5×10\^9 /L, or platelet count \< 100 ×10\^9/L, or hemoglobin \< 9 g/dL
Total bilirubin \> 1 ULN; SGOT (AST), SGPT (ALT), \> 1.5 ULN; for patient with liver metastasis，AST or ALT \> 3 ULN
Known HIV positive
Hypersensitivity to either of the investigation drugs
